Bill Would Give HIV/AIDS Clinics More Leeway to Use 340B Savings and Other Program Income

A bill has been introduced in Congress that would get rid of a major barrier that prevents Ryan White clinics from providing PrEP to those at high risk of contracting the HIV/AIDS virus.

U.S. Sens. Rick Scott (R-Fla.) and Ben Ray Luján (D-N.M.) have introduced a bill to let Ryan White clinics use income from being in the HIV/AIDS program to provide pre-exposure prophylaxis, or PrEP, a daily medication used to

Read More »

Feds Urge Appeals Court to Overrule Lower Court in AstraZeneca’s 340B Contract Pharmacy Lawsuit

The federal government wants an appeals court to rule that drug manufacturer AstraZeneca may not unilaterally dictate how many contract pharmacies a 340B covered entity may use to dispense 340B drugs.

The federal government told a federal appeals court in Philadelphia yesterday it should use “the familiar tools of statutory interpretation” to hold that drug manufacturer AstraZeneca may not unilaterally dictate how many contract pharmacies a 340B covered entity

Read More »

West Virginia Hardens its 340B Anti-discrimination Law to Explicitly Bar 340B Claims Modifiers

West Virginia has reinforced a 2019 law to bar PBMs or other payers from requiring hospitals such as CAMC and other health care providers to include claims modifiers when billing for 340B-purchased drugs.

A new West Virginia law clarifies that PBMs or other third-party payers may not require a drug claim “to include a modifier or be processed or resubmitted to indicate that the drug is a 340B drug.”

Please

Read More »

Bipartisan U.S. House Group Renewing Pressure on HHS to Punish Drug Makers Over 340B Pricing Denials

Clockwise from top left, Reps. Abigail D. Spanberger (D-Va.), Cindy Axne (D-Iowa), David McKinley (R-W.Va.), Doris Matsui (D-Calif.), John Katko (R-N.Y.), and Dusty Johnson (R-S.D.) are urging fellow House members to sign a letter urging HHS to begin 340B enforcement actions against drug companies.

Six U.S. House members—three Democrats and three Republicans—are urging fellow representatives to sign a letter asking U.S. Health and Human Services (HHS) Department leaders “to begin enforcement actions against pharmaceutical companies that refuse to honor 340B discounts on

Read More »

NACHC Hopes Congress Will Pass Laws Protecting 340B Providers This Year

NACHC “would love to see” Congress pass legislation by the end of this year protecting health centers from drug manufacturers and PBMs' restrictions on 340B access, NACHC Senior Vice President Joe Dunn said during a news conference yesterday.

The National Association of Community Health Centers “would love to see” Congress pass legislation by the end of this year that stops drug makers from restricting 340B contract pharmacy arrangements and stops pharmacy benefit managers from taking covered

Read More »

Arizona Lawmakers Pass and Send 340B Anti-discrimination Bill to Governor

Arizona lawmakers have sent Gov. Doug Ducey (R) legislation prohibiting various forms of pharmacy benefit manager discrimination against 340B covered entities.

Arizona lawmakers passed legislation last week prohibiting various forms of pharmacy benefit manager discrimination against 340B covered entities.

Please Login or Become a Paid Subscriber to View this Content

Read More »

Congress Turns House Floor to 340B For an Hour

Rep. Abigail Spanberger (D-Va.) organized an hour's worth of testimonials for 340B Tuesday night on the U.S. House floor.

Seven U.S. representatives—five Democrats and two Republicans—lauded the 340B program on the House floor Tuesday night during an hour of speeches organized by Rep. Abigail Spanberger (D-Va.) and co-hosted by Rep. John Rose (R-Tenn.).

Read More »

GlaxoSmithKline Ending Voluntary 340B Pricing on Two Orphan Drugs

GlaxoSmithKline is ending voluntary 340B pricing for rural and cancer hospitals on its blockbuster severe asthma drug Nucala and first-line advanced ovarian cancer drug Zejula.

In a blow to rural and cancer hospitals, U.K. drug manufacturer GlaxoSmithKline (GSK) is ending voluntary 340B pricing for them on its blockbuster severe asthma drug Nucala and first-line advanced ovarian cancer drug Zejula.

Read More »

340B Report Publisher and CEO: Momentum for 340B Protections Is Growing

340B healthcare providers have turned to the states to address challenges to the drug discount program, 340B Report Publisher and CEO Ted Slafsky says.

Safety net healthcare providers increasingly have turned to the states to address challenges to the 340B program, 340B Report Publisher and CEO Ted Slafsky says in his latest column for medication management solutions company Omnicell.

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
×

*Sign up for news summaries and alerts from 340B Report